By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Great Basin today announced it has filed for 510(k) clearance of its molecular diagnostic test for Clostridium difficile.

In addition to its application to the US Food and Drug Administration, the Salt Lake City firm said also that it plans to submit an application to the European Union by the end of the year to obtain CE marking for the test, and upon regulatory approvals in the US and Europe, the company will launch its assay and instrument immediately.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.